<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354587</url>
  </required_header>
  <id_info>
    <org_study_id>Hizentra</org_study_id>
    <nct_id>NCT01354587</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Tolerability of Hizentra®</brief_title>
  <official_title>Evaluation of Efficacy and Tolerability of Hizentra® in Subjects Transitioning From Vivaglobin® (16% SCIG Product) to Hizentra® (20% SCIG Product)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the changes in the Treatment Satisfaction&#xD;
      Questionnaire for Medication in the areas of effectiveness, side effects, and convenience of&#xD;
      administration of each medication in Primary Immunodeficiency Disorder (PIDD) subjects&#xD;
      transitioning from subcutaneous Vivaglobin® to Hizentra®.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will evaluate subjects with Primary Immunodeficiency Disorder (PIDD) who are&#xD;
      currently self-infusing Vivaglobin therapy for at least six months prior to changing to&#xD;
      Hizentra® therapy. Following screening and enrollment, subjects will continue to self-infuse&#xD;
      Vivaglobin® for seven infusions and then be converted to subcutaneous Hizentra® treatment&#xD;
      which they will continue for the next 6 months. The study will determine if Hizentra®&#xD;
      provides improved subject satisfaction by Treatment Satisfaction Questionnaire for&#xD;
      Medication. Diaries related to the local site reactions, the number of infusion sites per&#xD;
      subject/per dose, volume of Hizentra® per site, duration of infusions, systemic side effects&#xD;
      of the new medication and dose on IgG levels and antibody titers, and local site reactions&#xD;
      with Hizentra®.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the changes in the Treatment Satisfaction Questionnaire for Medication in PIDD subjects transitioning from subcutaneous Vivaglobin® to Hizentra®.</measure>
    <time_frame>32 weeks</time_frame>
    <description>Subjects complete the TSQM at each study visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the incidence of local site reactions in subjects self-infusing with Vivaglobin® transitioning to Hizentra®.</measure>
    <time_frame>32 weeks</time_frame>
    <description>Study subjects complete a weekly infusion diary that is collected at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the steady state IgG levels in subjects self-infusing with Vivaglobin® transitioning to Hizentra®.</measure>
    <time_frame>32 weeks</time_frame>
    <description>IgG levels are obtained at each visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Primary Immunodeficiency Disorders</condition>
  <arm_group>
    <arm_group_label>Hizentra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compare IgG levels and site reaction in subjects transitioning from Vivaglobin to Hizentra</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hizentra</intervention_name>
    <description>Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.</description>
    <arm_group_label>Hizentra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects currently self-infusing with Vivaglobin® for at least six months prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Diagnosis of antibody deficiency due to primary immune deficiency disease.&#xD;
&#xD;
          -  Stable serum IgG levels of &gt; 550 mg/dl while on Vivaglobin® based on two&#xD;
             determinations at least 8 weeks apart and obtained within 6 months of entry.&#xD;
&#xD;
          -  Willing to sign consent and follow study schedule.&#xD;
&#xD;
          -  1 year to 75 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of acute systemic illness or infection at within four weeks of screening or&#xD;
             enrollment.&#xD;
&#xD;
          -  Any serious grade 3 or greater toxicity at screening.&#xD;
&#xD;
          -  History of bleeding or chronic skin disorders.&#xD;
&#xD;
          -  Selective IgA deficiency in absence of other antibody deficiencies&#xD;
&#xD;
          -  History of anaphylactic or severe systemic reaction to Vivaglobin.&#xD;
&#xD;
          -  Pregnant or breastfeeding females.&#xD;
&#xD;
          -  Use of systemic pre-medication prior to SCIG.&#xD;
&#xD;
          -  Protein losing enteropathy or nephritic syndrome.&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator would interfere with the conduct&#xD;
             of the study.&#xD;
&#xD;
          -  Subject or guardian unwilling to sign consent or adhere to study schedule.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Sleasman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla Duff, MSN</last_name>
    <phone>7275533515</phone>
    <email>cduff@health.usf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Baldwin</last_name>
    <phone>7275531258</phone>
    <email>abaldwin@health.usf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Duff, MSN</last_name>
      <phone>727-553-3515</phone>
      <email>cduff@health.usf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Baldwin</last_name>
      <phone>7275531258</phone>
      <email>abaldwin@health.usf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Sleasman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carla Duff, MSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2011</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunodeficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

